Neurologic inflammation and oral disease. An aetiopathogenic hypothesis;L'infiammazione neuro-mediata e le patologie della mucosa orale: Un'ipotesi etiopatogetica

Recenti Progressi in Medicina

Volumn 98, Issue 12, 2007, Pages 653-658

  Scardina, Giuseppe Alessandro ^a   Ruggeri, Alessia ^a   Messina, Pietro ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Neurogenic inflammation; Neuropeptides; Oral disease

Indexed keywords

NEUROPEPTIDE;

HUMAN; INFLAMMATION; MOUTH DISEASE; NEUROGENIC INFLAMMATION; NEUROLOGIC DISEASE; NOCICEPTIVE STIMULATION; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICROCIRCULATION; MOUTH DISEASES; MOUTH MUCOSA; NEUROGENIC INFLAMMATION; NEUROPEPTIDES; NOCICEPTORS; PAIN; RATS; SUBSTANCE P; SWINE; TONGUE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 38749136330     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Bayliss W.M. On the origin from the spinal cord of the vaso-dilator fibres of the hind limb, and on the nature of these fibres." J Physiol 1901; 27: 173-209.
2. Lundy FT, Linden GJ. Neuropeptides and neurogenic mechanism in oral and periodontal inflammation. Crit Rev Oral Biol Med 2004; 15: 82-98.
3. Jancso N, Jancsò-Gabor A, Szolcsànyi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment by capsaicin. Br J Pharmac Chemother 1967; 31: 138-51.
4. Silver WL, Clapp TR, Stone LM, Kinnamon SC. TRPV1 receptors and nasal trigeminal chenesthesis. Chem Senses 2006; 31: 807-12. Epub 2006, August 14.
5. Reilly CA, Yost GS. Metabolism of capsaicinoids by P450 enzymes: a review of recent findings on reaction mechanisms, bioactivation and detoxification processes. Drug Metab Rev 2006: 38: 635-706.
6. Govindarajan VS, Sathyanarayana MN. Capsicum: production, technology. Chemistry and Quality, Part I - V, 1985-1991.
7. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999; 51: 159-212.
8. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001; 24: 487-517.
9. Sterner O, Szallasi A. Novel natural vanilloid receptor agonists: new therapeutic targets for drug development. Trends Pharmacol Sci 1999; 20: 459-65.
10. Walpole CS, Bevan S, Bovermann G, Boelsterli JJ, Breckenridge R, Davies JW, et al. The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J Med Chem 1994; 37: 1942-54.
11. Gunthorpe MJ, Benham CD, Randall A, Davis JB. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trend Pharmacol Sci 2002; 23: 183-191.
12. Ferrer-Montiel A, Garcia-Martinez C, Morenilla-Palao C, Garcia-Sanz N, Fernandez-Carvajal A, Fernandez-Ballester G, Planells-Cases R. Molecular architecture of the vanilloid receptor. Insights for drug design. Eur J Biochem 2004; 271: 1820-6.
13. Elitt CM, McIlwrath SL, Lawson JJ, Malin SA, Molliver DC, Cornuet PK, et al. Artemin overexpression in skin enhances expression of TRPV1 and TRPA1 in cutaneous sensory neurons and leads to behavioral sensitivity to heat and cold. J Neurosci 2006; 26: 8578-87.
14. Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, et al. A TRP channel that senses cold stimuli and menthol. Cell 2002; 108: 705-15.
15. Szallasi A, Appendino G. Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse? J Med Chem 2004; 47: 2717-23.
16. Mellor IR, Ogilvie J, Pluteanu F, Clothier RH, Parker TL, Rosini M, et al. Methoctramine analogues inhibit responses to capsaicin and protons in rat dorsal root ganglion neurons. Eur J Pharmacol 2004; 505: 37-50.
17. Garcia-Martinez C, Morenilla-Palao C, Planells-Cases R, Merino JM, Ferrer-Montiel A. Identification of an aspartic residue in the P-loop of the vanilloid receptor that modulates pore properties. J Biol Chem 2000; 275: 32552-8.
18. Swanson DM, Dubin AE, Shah C, Nasser N, Chang L, Dax SL, et al. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl) piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J Med Chem 2005; 48: 1857-72.
19. Moskowitz MA, Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Medicine 2002; 8: 136-42.
20. Holmgren S, Jensen J. Evolution of vertebrate neuropeptides. Brain Res Bull 2001; 55: 723-35.
21. Brain SD, Williams TJ. Substance P regulates the vasodilatator activity of calcitonin gene-related peptide. Nature 1988; 335: 73-5.
22. Kenins P, Hurley JV, Bell C. The role of substance P in the axon reflex in the rat. Br J Dermatol 1984; 111: 551-9.
23. Lee T, Kawai Y, Shiosaka S. Coexistence of calcitonin gene related peptide and subtance P-like peptide in single cells of the trigeminal ganglion of the rat: immunohistochemical analysis. Brain Res 1985; 330: 194-6.
24. Rosell S, Olgart L, Gazelius B, Panopoulos P, Folkers K, Horig J. Inibition of antidromic and substance P-induced vasodilation by a substance P antagonist. Acta Physiol Scand 1981; 111: 381-2
25. Scardina GA, Augello L, Messina P. The role of neuromodulators (substance P and calcitonin gene-related peptide) in the development of neurogenic inflammation in the oral mucosa. Minerva Stomatol 2004; 53: 21-32.
26. Brain SJ, Morris H, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilatator. Nature 1985; 313: 54-56.
27. Ulrich-Lai YM, Flores CM, Harding-Rose CA, Goodis HE, Hargreaves KM. Capsaicin-evoked release of immunoreactive calcitonin gene-related peptide from rat trigeminal ganglion: evidence for intraganglionic neurotransmission. Pain 2001; 91: 219-26.
28. Pozo D, Delgado M, Martinez C, Guerrero JM, Leceta J, Gomariz RP, et al. Immunobiology of vasoactive intestinal peptide (VIP) . Immunol Today 2000; 21: 7-11.
29. Ganea D, Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med 2002; 13: 229-37.
30. Pasqualino A, Nesci E. Anatomia umana fondamentale. Torino: UTET. Pagg. 131-3; 393-4; 428-31.
31. Ten Cate AR. Oral histology: development, structure, and function. Fourth ed; II: 15-30.
32. Messina P, Scardina GA, Garofalo G, Esame video-capillaroscopico della mucosa orale. Evoluzione delle tecniche. Dental Cadmos 2002; 9: 95-106.
33. Scardina GA, Messina P. Study of the microcirculation of oral mucosa in healthy subjects. It J Anat Embryol 2003; 108: 39-48.
34. Scardina GA. The effect of cigar smoking on lingual microcirculation. Odontology 2005; 93: 41-5
35. Yiangou Y, Facer P, Dyer NHC, Chan CLH, Knowles C, Williams NS. Vanilloid receptor 1 immuno reactivity in inflamed human bowel. Lancet 2001; 357: 1338.
36. Chahal LA. Antidromic vasodilatation and neurogenic inflammation. Pharmacol Ther 1988; 37: 275-300.
37. Epstain JB, Marcoe JH. Topical application of capsaicin for treatment of oral neuropatic pain and trigeminal neuralgia. Oral Surg Oral Med Oral Pathol 1994; 77: 135-40.
38. Herbert MK, Holzer P. Neurogenic inflammation. Anasthesiol Intens Med 2002; 37: 314-25.
39. Hou M, Uddman R, Tajti J, Kanje M, Edvinsson L. Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Nuerosci Lett 2002; 330: 223-7.
40. Kemppainen P, Avellan H, Handwerker HO, Forster C. Difference between tooth stimulation and capsaicin-induced neurogenic vasodilatation in human ginigiva. J Dent Res 2003; 82: 303-7.
41. Franco-Cereceda A, Henke H, Lundberg JM, Petermann JB, Hokfelt T, Fischer JA. Calcitonin gene-related peptide (CGRP) in capsaicin sensitive substance P-immunoreactive sensory neurons in animals and man: distribution and release by capsaicin. Peptides 1987; 8: 399-410.
42. Fazekas A, Vindisch k, Posch E, Gyorfi A. Experimentally-induced neurogenic in the rat oral mucosa. J Periodontal Res 1990; 25: 276-82.
43. Gyorfi A, Fazekas A, Rosivall L. Neurogenic inflammation and oral mucosa. J Clin Periodontol 1992; 19: 731-6.
44. Flores CM, Leong AS, Dussor GO, Hardine RC, Hargreaves KM, Kilo S. Capsaicin-evoked CGRP release from rat buccal mucosa: development of a model system for studying trigeminal machanisms of neurogenic inflammation. Eur J Neurosci 2001; 14: 1113-20.
45. Dray A. Inflammatory mediators of pain. Br J Anaesth 1995; 75: 125-31.
46. Gamse R, Posch M, Saria A, Jancsò G. Several mediators appear to interact in neurogenic inflammation. Acta Physiol Hung 1987; 69: 343-54.
47. Sawynok J. Topical and peripherally acting analgesic. Pharmacol Rev 2003; 55: 1-20.
48. Verdickt GM, Abbot PV. Blood flow changes in human dental pulps when capsaicin is applied to the adjacent gingival mucosa. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 561-5.
49. Bongenhielm U, Boissonade FM, Westermark A, Robinson PP, Fried K. Sympathetic nerve sprouting fails to occur in the trigeminal ganglion after peripheral nerve injury in the rat. Pain 1999; 82: 283-8.
50. Couture R, Cuello AC, Henry JL. Trigeminal antidromic vasodilatation and plasma extravation in the rat: effects of sensory, autonomic and motor denervation. Brain Res 1985; 346: 108-114
51. Scardina GA, Carini F, Messina P. Vasodilatation of human gengiva and neurogenic inflammation. Clinical Hemoreology and Microcirculation 2005; 32: 279-85.
52. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-24.
53. Lin Q, Zou X, Fang L, Willis WD. Sympathetic modulation of acute flare induced by intradermal injection of capsaicin in anesthetized rats. J Neurophysiol 2003; 89: 853-61.
54. Liu M, Pertl C, Markowitz K, Dorscher KJ, Kim S. The effects of capsaicin on pulpar blood flow. Proc Finn Dent Soc 1992; 88 suppl 1: 463-7.
55. Scardina GA, Messina P. Microvascular characteristics of the human filiform papillae: a videocapillaroscopic study. Ann Anat 2006; 188: 163-6.